Stockreport

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Compass Therapeutics, Inc.  (CMPX) 
PDF Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on [Read more]